Enhancing immune responses to limit chronic immune activation during SIV.
Where this comes from
- Record sourced from PubMed, PMID 22523060.
- Also identified by DOI 10.1172/JCI63389 and PMC identifier 3337001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The persistent immune activation that is typical of HIV-1 and SIV infection results in exhaustion and dysfunction of T and B cells; in T cells, this is marked by increased expression and signaling through the inhibitory receptor programmed death-1 (PD-1). Targeting this exhaustion pathway could result in improved antiviral immune responses, but there have been concerns that it would also lead to increased inflammation and immunopathology. In this issue of the JCI, Dyavar Shetty et al. demonstrate that blocking PD-1 actually reduced proinflammatory responses and improved immunity in the gut of SIV-infected rhesus macaques, suggesting that this might have therapeutic potential to prevent opportunistic infections in HIV-infected patients.
Medical subject headings
- Antibodies, Neutralizing
- Antiviral Agents
- Bacterial Translocation
- Interferon Type I
- Programmed Cell Death 1 Receptor
- Simian Acquired Immunodeficiency Syndrome